Advocacy intelligence hub — real-time data for patient organizations
University of California, San Francisco — PHASE1, PHASE2
University of Pittsburgh — NA
Sovargen — PHASE1, PHASE2
GRIN Therapeutics, Inc. — PHASE1, PHASE2
Boston Children's Hospital
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis news →
Darcy Krueger, MD, PhD, MD
Children's Hospital Medical Center, Cincinnati
📍 CINCINNATI, OH
Mustafa Sahin, MD, PhD, MD
Boston Children's Hospital
📍 BOSTON, MA
David N Franz
Children's Hospital Medical Center, Cincinnati
Nicole McDonald
University of California, Los Angeles
Shoufeng Li, Ph.D
Aucta Pharmaceuticals, Inc
Julian Sampson
Cardiff University
View all Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis specialists →